Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression

Abstract

BackgroundCrenolanib is a tyrosine kinase inhibitor targeting PDGFR-α, PDGFR-β and Fms related tyrosine kinase-3 (FLT3) that is currently evaluated in several clinical trials. Although platelet-derived growth factor receptor (PDGFR) signalling pathway is believed to play an important role in angiogenesis and maintenance of functional vasculature, we here demonstrate a direct angiostatic activity of crenolanib independently of PDGFR signalling.MethodsThe activity of crenolanib on cell viability, migration, sprouting, apoptosis and mitosis was assessed in endothelial cells, tumour cells and fibroblasts. Alterations in cell morphology were determined by immunofluorescence experiments. Flow-cytometry analysis and mRNA expression profiles were used to investigate cell differentiation. In vivo efficacy was investigated in human ovarian carcinoma implanted on the chicken chorioallantoic membrane (CAM).ResultsCrenolanib was found to inhibit endothelial cell viability, migration and sprout length, and induced apoptosis independently of PDGFR expression. Treated cells showed altered actin arrangement and nuclear aberrations. Mitosis was affected at several levels including mitosis entry and centrosome clustering. Crenolanib suppressed human ovarian carcinoma tumour growth and angiogenesis in the CAM model.ConclusionsThe PDGFR/FLT3 inhibitor crenolanib targets angiogenesis and inhibits tumour growth in vivo unrelated to PDGFR expression. Based on our findings, we suggest a broad mechanism of action of crenolanib.

Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib

“…Moreover, although axitinib was designed as a selective VEGFR inhibitor, it has inhibitory effects on more proteins, such as FGFRs Aurora, ABL and MAPK family kinases [39,40]. Indeed, we have recently shown that targeted TKI activity is not always directly related to its designated targets [41]. Additionally, the difference in sensitivity might be explained by slightly different drug target expressions.…”

The Role of Heparan Sulfate and Neuropilin 2 in VEGFA Signaling in Human Endothelial Tip Cells and Non-Tip Cells during Angiogenesis In Vitro

“…Specific VLDL uptake by CD34 - cells may be explained by its role in angiogenesis as a provider of biomass for proliferating stalk cells [ 33 ]. We tested the possible consequences of inhibition of VLDL uptake on the percentage tip cells and on vessel sprouting in the spheroid model.…”

Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma

“…Similarly, we have recently discovered that crenolanib, a known PDGFR inhibitor, acts on tumour endothelial cells, a mechanism that is not always directly related to its designated targets. 38 Since resistance to sunitinib is a frequent event in the clinical management of RCC, one way to overcome this challenge is the optimisation of high-order drug mixtures to kill drug-resistant cancer cells. 19,39 Notably, treatment with relatively low-dosed ODCs was effective also in cells chronically pre-treated with sunitinib.…”